Bath & Body Works: The Turnaround Formula Gets Its First Report Card Before Market Open

Bath & Body Works (BBWI) reports first-quarter fiscal 2026 earnings before market open on May 27, with analysts expecting $0.29 per share on what is shaping up to be a pivotal test of the company's Consumer First Formula turnaround strategy. The report comes as BBWI navigates a challenging retail environment marked by declining sales guidance, aggressive brand repositioning, and mounting pressure to prove its innovation and marketplace expansion initiatives can reverse negative momentum.

Part 1: Earnings Preview

Bath & Body Works operates as a specialty retailer of home fragrance, body care, and soap products through approximately 1,800 company-operated stores in the U.S. and Canada, plus international franchises and e-commerce channels. The company is a dominant player in the home fragrance category but faces intensifying competition and shifting consumer preferences.

BBWI will report fiscal Q1 2026 results before the open on May 27, with the consensus estimate calling for $0.29 per share. The company most recently reported $2.05 per share for the fiscal fourth quarter ended January 31, 2026, beating estimates of $1.77. Comparing to the same quarter last year, the $0.29 estimate represents a 40.82% decline from the $0.49 reported in Q1 2025, underscoring the significant headwinds facing the business.

Three key themes define this earnings story:

Consumer First Formula Execution: Since launching this strategic initiative in Q3 2025, management has accelerated innovation in hero categories, refreshed brand identity, and expanded distribution channels including an earlier-than-planned Amazon launch. Investors will scrutinize whether these moves are gaining traction or merely offsetting deeper structural challenges in the core business.

Sales Trajectory and Guidance Credibility: Management's full-year 2026 guidance calls for net sales to decline 4.5% to 2.5% compared to fiscal 2025's $7.29 billion, with Q1 expected down 6% to 4%. After missing Q3 2025 estimates and delivering only modest beats in recent quarters, investors need evidence that the company can stabilize traffic and conversion trends.

Margin Pressure and Cost Management: With adjusted EPS guidance of $2.40 to $2.65 for fiscal 2026 (down from $3.21 in fiscal 2025), the company faces significant margin compression. Operating income fell to $1.13 billion in fiscal 2025 from $1.27 billion the prior year, and investors will watch closely for signs that promotional intensity and brand repositioning costs are stabilizing.

Analyst commentary ahead of the release reflects cautious positioning. The consensus holds at 3.35 (Hold) with 17 analysts covering the stock, though sentiment has deteriorated from a month ago. The mean price target of $24.15 implies meaningful upside from current levels, but the wide range ($19.00 to $30.00) suggests significant disagreement about the turnaround's probability of success.

Part 2: Historical Earnings Performance

Bath & Body Works has delivered a mixed earnings track record over the past four quarters, with two beats, one in-line result, and one notable miss. The company reported $0.49 in Q1 2025 (beating the $0.47 estimate by 4.26%), met expectations exactly at $0.37 in Q2 2025, then missed badly in Q3 2025 with $0.35 versus the $0.40 estimate (a 12.50% shortfall). The most recent quarter saw a strong rebound, with $2.05 crushing the $1.77 estimate by 15.82%.

The pattern reveals heightened volatility in execution, particularly around the critical holiday quarter where BBWI missed despite typically strong seasonal performance. The Q4 beat appears to reflect both better-than-feared holiday results and early traction from strategic initiatives, but the magnitude of the year-over-year decline expected for the upcoming quarter (down over 40%) suggests the market remains skeptical about sustainability. The company's ability to consistently meet or beat estimates has deteriorated compared to the more reliable beat pattern seen in 2023-2024, raising questions about visibility and guidance conservatism heading into this release.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Bath & Body Works typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior around BBWI earnings shows extreme volatility, with an average absolute Day 0 move of 11.20% and intraday range of 7.94%. The most recent eight earnings events have produced dramatic swings in both directions: the November 2025 report triggered a devastating 24.81% decline, while November 2024 saw a 16.51% surge. The February 2025 and June 2024 reports both produced double-digit declines exceeding 12%.

Day +1 follow-through averages 2.81% with a 5.08% range, suggesting initial reactions tend to stick but with meaningful intraday volatility. Notably, several recent reports have seen Day 0 declines followed by modest Day +1 recoveries, indicating potential overreaction patterns. The data reveals BBWI as a high-beta earnings event where execution and guidance can drive massive single-session moves, with recent volatility skewed heavily to the downside as the turnaround story faces mounting skepticism.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.16% ($1.62) for the upcoming earnings event, which sits below the 11.20% average historical Day 0 move but well within the range of recent outcomes. This suggests options traders are anticipating significant volatility but perhaps less extreme than the November 2025 disaster, potentially reflecting some stabilization in expectations around the turnaround narrative.

Part 3: What Analysts Are Saying

Analyst sentiment on Bath & Body Works reflects cautious skepticism heading into the report. The current consensus rating stands at 3.35 (Hold) across 17 analysts, with the breakdown showing 3 Strong Buys, 0 Moderate Buys, 14 Holds, and no sell ratings. This heavily hold-weighted distribution signals that most analysts are taking a wait-and-see approach to the turnaround story rather than making strong directional calls.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.38 to 3.35 and one analyst downgrading from Hold to a more cautious stance. The shift reflects growing concerns about the company's ability to execute against aggressive sales decline guidance while maintaining margin discipline.

The mean price target of $24.15 implies 36.2% upside from the current price of $17.73, suggesting analysts see meaningful value if the turnaround gains traction. However, the wide target range from $19.00 to $30.00 reveals significant disagreement, with bears seeing limited upside and bulls pricing in successful execution of the Consumer First Formula. The concentration of Hold ratings indicates most analysts want to see concrete evidence of sales stabilization and margin improvement before upgrading their stance.

Part 4: Technical Picture

Bath & Body Works enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing a 100% Sell signal, up from 88% Sell a week ago and 72% Sell a month ago. The intensifying bearish signal reflects accelerating downside momentum as the stock has failed to hold key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative heading into the report
• Medium-term (100% Sell): Bearish reading confirms weakness extends beyond immediate price action into the intermediate trend
• Long-term (100% Sell): Sell signal across all timeframes reflects comprehensive technical deterioration with no pockets of strength

Trend Characteristics: The Average strength and Average direction suggest the downtrend is persistent but not yet reaching climactic extremes, indicating potential for further downside if earnings disappoint.

The stock is trading at $17.73, positioned below all major moving averages beyond the 10-day: above the 5-day ($17.16) and 10-day ($17.49) but below the 20-day ($18.27), 50-day ($18.70), 100-day ($20.47), and 200-day ($22.44).

The technical setup is decidedly bearish heading into earnings, with the stock trapped below all meaningful resistance levels and showing no signs of stabilization. The 20-day moving average at $18.27 represents immediate overhead resistance, while the 50-day at $18.70 marks a more significant hurdle. The widening gap to the 200-day moving average at $22.44 illustrates the extent of technical damage, with the stock down over 21% from that long-term trend line. Given the uniformly bearish signals across all timeframes and the stock's position well below key moving averages, the technical picture offers no support heading into what is likely to be a volatile earnings event. Any positive surprise would face multiple layers of overhead resistance, while disappointment could accelerate the existing downtrend toward the $16 level.